Latest researches have proposed that as a marker for cancer stem cells (CSCs), CD133 expression indicates the poorer prognosis in GC patients and that the indication of CD133+ is consistent with the poorer prognosis prediction results of commonly used clinical pathological factors [12, 13]. This evidence concerns the gene PROM1 and cancer.